Analytical Data
-
Gene name
PSMA7
- Application
-
Alternative Names
PSMA7;HSPC;Proteasome subunit alpha type-7
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O14818
-
Expression Region
1-248aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MSYDRAITVF SPDGHLFQVE YAQEAVKKGS TAVGVRGRDI VVLGVEKKSV AKLQDERTVR KICALDDNVC MAFAGLTADA RIVINRARVE CQSHRLTVED PVTVEYITRY IASLKQRYTQ SNGRRPFGIS ALIVGFDFDG TPRLYQTDPS GTYHAWKANA IGRGAKSVRE FLEKNYTDEA IETDDLTIKL VIKALLEVVQ SGGKNIELAV MRRDQSLKIL NPEEIEKYVA EIEKEKEENE KKKQKKAS
-
Molecular Weight
30 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The PSMA7 (Proteasome Subunit Alpha Type 7) protein is a crucial component of the 26S proteasome, a multi-catalytic protein complex responsible for degrading ubiquitinated proteins and regulating various cellular processes, including the cell cycle, signal transduction, and immune responses. Research on PSMA7 has gained prominence due to its involvement in numerous pathophysiological conditions, including cancer and neurodegenerative diseases. Increased PSMA7 expression has been associated with tumor progression and drug resistance in several cancer types, suggesting its potential as a biomarker for prognosis and a target for therapeutic intervention. Additionally, its role in the regulation of the immune system has opened avenues for exploring PSMA7 as a target in immunotherapy. Understanding the structural and functional properties of PSMA7, along with developing recombinant forms of the protein, enables researchers to investigate its mechanisms of action and interactions within the proteasome complex. This knowledge could pave the way for novel therapeutic strategies aimed at modulating proteasomal activity and improving treatment outcomes in diseases where PSMA7 plays a pivotal role. Therefore, the study of PSMA7 is not only vital in elucidating fundamental cellular mechanisms but also holds significant promise for therapeutic developments in oncology and beyond.
